ALPMF News and Press, Astellas Pharma Inc From 04/27/22

Astellas Pharma, Inc. (ALPMF) Q4 2022 Results Conference Call April 27, 2022 01:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Kenji Yasukawa - President and CEO Bernie Zeiher - Chief Medical Officer Yukio Matsui - Chief Commercial Officer Minoru Kikuok...

Astellas Pharma press release (OTCPK:ALPMF): FY GAAP EPS of ¥103.03. Revenue of ¥1296.16B (+3.7% Y/Y) beats by ¥1285.85B. For further details see: Astellas Pharma GAAP EPS of ¥103.03, revenue of ¥1296.16B beats by ¥1285.85B

ESSA Pharma developed a novel mode of action drug, EPI-7386, for the treatment of metastatic castrate-resistant prostate cancer. Pre-clinical and early Ph 1 results are promising. ESSA's share price crashed in mid-Aug when a change in the Ph 1 trial protocol was announced, and a delay...

Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, trusts, and offshore funds. Tweedy,...

Astellas Pharma (OTCPK:ALPMF): 1H Non-GAAP EPS of ¥53.30; GAAP EPS of ¥38.65. Revenue of ¥651.66B (+5.9% Y/Y) Press Release For further details see: Astellas Pharma reports 1H results

Astellas Pharma (OTCPK:ALPMY) and Seagen (NASDAQ:SGEN) have announced that Japan's Ministry of Health, Labour and Welfare has approved PADCEV (enfortumab vedotin) for radically unresectable urothelial carcinoma that has progressed after anti-cancer chemotherapy. The New Drug Application ...

Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious, rare, and life-threatening diseases. Acer submitted an NDA for its lead drug candidate ACER-001 for treatment of UCDs in early August. Acer expects notification ...

Raymond James has upgraded FibroGen (NASDAQ:FGEN) to market perform from underperform after the company joined Astellas Pharma (OTCPK:ALPMF) on Thursday to announce the European approval of EVRENZO (roxadustat) for adults with anemia linked to chronic kidney disease (CKD). FibroGen (FGEN...

The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Astellas Pharma Inc. 2021 Q2 - Results - Earnings Call Presentation

The U.S. FDA has granted Astellas Pharma ([[ALPMF]]) and Seagen's ([[SGEN]] -0.4%) PADCEV (enfortumab vedotin-ejfv) expanded approval for a new indication to treat certain patients with urothelial cancer.The approval allows for the use of PADCEV for adult patients with locally advan...